| [1] |
LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan.
Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785.
|
| [2] |
LI Dong, ZHAO Yan.
Roles of National Arthroplasty Registries in Post-Market Surveillance of Medical Devices
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 640-644.
|
| [3] |
LU Zhenkai, YANG Dingquan, XIE Zhennian, WANG Lianxin, LI Yuanyuan, WANG Zhifei, CUI Xin, XIE Yanming.
Interpretation and insights from the “Guidelines for Pharmacovigilance of Topical Traditional Chinese Medicines in Clinical Applications”
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1029-1033.
|
| [4] |
LIN Lu, ZHAN Luchuan, LIU Xiaoqi, LIU Ju'e, WANG Laiyou, ZENG Ying, LAI Weihua.
Establish triggers for active monitoring of digoxin adverse events based on the China hospital pharmacovigilance system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1039-1043.
|
| [5] |
LI haiyan, YANG Zhongxu, LIU Yuekun, WANG Lihong.
Pharmaceutical care of serious adverse reactions due to methotrexate treatment of ectopic pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 454-456.
|
| [6] |
ZHANG Qi, CHEN Min, ZHANG Shiqing.
Conditional approval of medical devices in the United States and enlightenment
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1007-1010.
|
| [7] |
.
Annual report of national adverse drug reaction monitoring (2022)
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 712-719.
|
| [8] |
ZHAO Yan, LIU Wenbo, ZHAO Yifei, LI Dong, ZHENG Lijia, SONG Yana, ZHAO Yujuan, DONG Fang.
Applicability of patient registry research to regulation of medical devices
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 423-427.
|
| [9] |
ZHAO Yan, LI Dong, CHENG Yinjie, JIANG Bin, ZHAO Yifei, DONG Fang, YUAN Jing.
Advances in studies on post-market safety data sources and signal detection for medical devices
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 236-240.
|
| [10] |
ZHAO Yan, LI Yao, SONG Ya’na, ZHENG Lijia, LI Dong, ZHAO Yifei, BIAN Rongrong, DONG Fang.
Post-marketing active monitoring of medical devices under vigilance
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1385-1390.
|
| [11] |
ZHENG Yi, ZHAI Yinghong, GUO Xiaojing, XU Jinfang, CHI Lijie, GUO Zhijian, CHEN Chenxin, LIANG Jizhou, WEI Lianhui, CHEN Xiao, YE Xiaofei, HE Jia.
Thyroid immune-related adverse reactions of immune checkpoint inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 92-95.
|
| [12] |
SHEN Chuanyong, SONG Yana, ZHAO Yan, ZHENG Lijia, ZHAO Yifei, LI Dong.
Thoughts on constructing vigilance system of Chinese medical device in the new era
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 697-701.
|
| [13] |
TENG Yingying, LI Chaiquan, XU Yang, TANG Xun, GAO Pei.
Progress in the application of real-world data in post-market surveillance of medical devices
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 233-238.
|
| [14] |
LIANG Jiaqi, SHAO Rong, LIU Pengcheng, LI Ming, RENG Jingtian, TANG Ren, WANG Yue.
Characteristics of dear health care provider letters in Europe and America
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 275-278.
|
| [15] |
CUI Huanhuan, PEI Xiaojing, LI Yanrong, LIU Wendong, WANG Haixue, LAN Gongtao, WANG Tao.
The practice and consideration of pharmacovigilance during clinical trials in China
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1050-1054.
|